Brokerages expect that VERONA PHARMA P/S (NASDAQ:VRNA) will announce earnings of ($0.49) per share for the current quarter, Zacks reports. Zero analysts have made estimates for VERONA PHARMA P/S’s earnings, with the lowest EPS estimate coming in at ($0.57) and the highest estimate coming in at ($0.41). VERONA PHARMA P/S posted earnings of ($0.91) per share in the same quarter last year, which suggests a positive year over year growth rate of 46.2%. The business is scheduled to report its next quarterly earnings results on Tuesday, November 6th.
Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover VERONA PHARMA P/S.
VERONA PHARMA P/S (NASDAQ:VRNA) last posted its earnings results on Tuesday, August 7th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $1.20.
An institutional investor recently raised its position in VERONA PHARMA P/S stock. Foresite Capital Management III LLC increased its holdings in VERONA PHARMA P/S (NASDAQ:VRNA) by 7.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 565,292 shares of the company’s stock after purchasing an additional 36,870 shares during the quarter. VERONA PHARMA P/S makes up 2.5% of Foresite Capital Management III LLC’s investment portfolio, making the stock its 12th biggest holding. Foresite Capital Management III LLC owned approximately 4.31% of VERONA PHARMA P/S worth $11,306,000 as of its most recent SEC filing. Institutional investors and hedge funds own 49.47% of the company’s stock.
Shares of NASDAQ VRNA traded down $0.60 during midday trading on Thursday, reaching $12.50. 8,191 shares of the company were exchanged, compared to its average volume of 2,289. VERONA PHARMA P/S has a one year low of $10.44 and a one year high of $25.55.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Featured Story: Calculate Your Return on Investment (ROI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.